Prime Medicine (PRME) Cash from Financing Activities (2021 - 2026)

Prime Medicine has reported Cash from Financing Activities for 6 years, with the latest figure at $393000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 93.45% year-over-year to $393000.0; the trailing twelve-month figure through Mar 2026 stood at $145.9 million (up 227.52% YoY), and the FY2025 full-year result was $151.5 million, down 22.65% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $393000.0, down from $562000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $184.1 million in Q4 2022, with the low at -$1.3 million in Q1 2022.
• Historically, Cash from Financing Activities has averaged $31.2 million across 5 years, with a median of $197000.0 in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 99.89% — and 2024, when it soared 231263.24%.
• Prime Medicine's Cash from Financing Activities stood at $184.1 million in 2022, then slumped by 99.89% to $194000.0 in 2023, then plunged by 99.48% to $1000.0 in 2024, then soared by 56100.0% to $562000.0 in 2025, then plunged by 30.07% to $393000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $393000.0 (Q1 2026), $562000.0 (Q4 2025), and $144.8 million (Q3 2025), per Business Quant data.